Aug. 14, 2013

Lupus Clinical Research Study Continues to Seek Patients to Enroll

A national study to help advance lupus research is still enrolling participants. The EMBODY program is a clinical research study evaluating an investigational medication for lupus.

This global clinical research study is being conducted to assess the effects of an investigational medication called epratuzumab. The main purpose of this research program is to evaluate if epratuzumab can safely and effectively reduce the signs and symptoms of lupus and the amount of corticosteroids needed to control symptoms. Epratuzumab targets specific cells that are part of the immune system. Epratuzumab is being evaluated to see if can help prevent the immune system from attacking healthy tissue, help reduce the level of inflammation and improve the symptoms associated with lupus.

There is currently no cure for lupus. In fact, in the past 50 years, there has been only one medication approved for lupus. While there are several medications used to help reduce the signs and symptoms of lupus, many have serious side effects. Long-term use can cause damage to the body's organs. There is an ongoing need to develop new treatment options for people with lupus that are safe and effective.

Chances are you probably know someone else who is affected by lupus. You may have friends or family members who are living with this disease. Please share this information with them and encourage them to visit lupus.org/clinicaltrials/Embody.html or call 1.800.558.0121 for more information.